252 related articles for article (PubMed ID: 33152071)
1. Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Floris G; Richard F; Hamy AS; Jongen L; Wildiers H; Ardui J; Punie K; Smeets A; Berteloot P; Vergote I; De Croze D; Meseure D; Salomon A; Laé M; Reyal F; Biganzoli E; Neven P; Desmedt C
J Natl Cancer Inst; 2021 Feb; 113(2):146-153. PubMed ID: 33152071
[TBL] [Abstract][Full Text] [Related]
2. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
[TBL] [Abstract][Full Text] [Related]
3. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
4. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer.
Zhang L; Wang XI; Zhang S
Hum Pathol; 2018 Oct; 80():47-54. PubMed ID: 29883779
[TBL] [Abstract][Full Text] [Related]
6. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Candelaria RP; Spak DA; Rauch GM; Huo L; Bassett RL; Santiago L; Scoggins ME; Guirguis MS; Patel MM; Whitman GJ; Moulder SL; Thompson AM; Ravenberg EE; White JB; Abuhadra NK; Valero V; Litton J; Adrada BE; Yang WT
Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S35-S41. PubMed ID: 34272161
[TBL] [Abstract][Full Text] [Related]
7. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
8. Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.
Barba M; Vici P; Pizzuti L; Di Lauro L; Sergi D; Di Benedetto A; Ercolani C; Sperati F; Terrenato I; Botti C; Mentuccia L; Iezzi L; Gamucci T; Natoli C; Vitale I; Mottolese M; De Maria R; Maugeri-Saccà M
BMC Cancer; 2017 Feb; 17(1):101. PubMed ID: 28166748
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers.
Ruan M; Tian T; Rao J; Xu X; Yu B; Yang W; Shui R
Diagn Pathol; 2018 Aug; 13(1):66. PubMed ID: 30170605
[TBL] [Abstract][Full Text] [Related]
10. Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.
Liu YL; Saraf A; Catanese B; Lee SM; Zhang Y; Connolly EP; Kalinsky K
Breast Cancer Res Treat; 2018 Jan; 167(1):277-288. PubMed ID: 28948418
[TBL] [Abstract][Full Text] [Related]
11. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
[TBL] [Abstract][Full Text] [Related]
12. High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy.
Wood SJ; Gao Y; Lee JH; Chen J; Wang Q; Meisel JL; Li X
Breast Cancer Res Treat; 2024 May; 205(1):193-199. PubMed ID: 38286889
[TBL] [Abstract][Full Text] [Related]
13. [Correlation analysis of PD-L1 expression and prognosis in triple-negative breast cancers].
Pan BJ; Xu C; Ping GQ; Song GX; Zhang WM; Wang C; Zhang ZH
Zhonghua Bing Li Xue Za Zhi; 2017 Dec; 46(12):822-826. PubMed ID: 29224274
[No Abstract] [Full Text] [Related]
14. Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy.
Jongen L; Floris G; Wildiers H; Claessens F; Richard F; Laenen A; Desmedt C; Ardui J; Punie K; Smeets A; Berteloot P; Vergote I; Neven P
Breast Cancer Res Treat; 2019 Aug; 176(3):699-708. PubMed ID: 31106385
[TBL] [Abstract][Full Text] [Related]
15. Relationship Between the Neutrophil to Lymphocyte Ratio, Stromal Tumor-infiltrating Lymphocytes, and the Prognosis and Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer.
Pang J; Zhou H; Dong X; Wang S; Xiao Z
Clin Breast Cancer; 2021 Dec; 21(6):e681-e687. PubMed ID: 34001439
[TBL] [Abstract][Full Text] [Related]
16. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
17. Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.
O'Loughlin M; Andreu X; Bianchi S; Chemielik E; Cordoba A; Cserni G; Figueiredo P; Floris G; Foschini MP; Heikkilä P; Kulka J; Liepniece-Karele I; Regitnig P; Reiner A; Ryska A; Sapino A; Shalaby A; Stovgaard ES; Quinn C; Walsh EM; Zolota V; Glynn SA; Callagy G
Breast Cancer Res Treat; 2018 Aug; 171(1):1-9. PubMed ID: 29774470
[TBL] [Abstract][Full Text] [Related]
18. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
19. CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer.
Cerbelli B; Botticelli A; Pisano A; Pernazza A; Campagna D; De Luca A; Ascierto PA; Pignataro MG; Pelullo M; Rocca CD; Marchetti P; Fortunato L; Costarelli L; d'Amati G
Virchows Arch; 2020 Apr; 476(4):569-576. PubMed ID: 31853625
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
